Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 341

1.

Combination chemotherapy of solid tumors: an American-Italian collaboration: a celebration of the work of Gianni Bonadonna.

DeVita VT, Canellos GP.

Tumori. 2016 Mar-Apr;102(2):124-6. doi: 10.5301/tj.5000492. Epub 2016 Mar 22. Review.

PMID:
27002947
2.

Vincent T. DeVita on His New Book, "The Death of Cancer," and the Current State of Cancer Care.

DeVita VT.

Oncology (Williston Park). 2016 Mar;30(3):210. No abstract available.

3.

Intensive Combination Chemotherapy and X-Irradiation in Hodgkin's Disease.

DeVita VT Jr, DeVita-Raeburn E, Moxley JH 3rd.

Cancer Res. 2016 Mar 15;76(6):1303-4. doi: 10.1158/0008-5472.CAN-16-0470. No abstract available.

4.

Gianni Bonadonna, MD: 1934-2015.

Surbone A, DeVita VT Jr.

Cancer. 2016 Jan 15;122(2):176-7. doi: 10.1002/cncr.29752. Epub 2015 Oct 20. No abstract available.

5.

Clinical cancer research: the past, present and the future.

DeVita VT Jr, Eggermont AM, Hellman S, Kerr DJ.

Nat Rev Clin Oncol. 2014 Nov;11(11):663-9. doi: 10.1038/nrclinonc.2014.153. Epub 2014 Sep 23. Review.

PMID:
25245981
6.

Treatment of Hodgkin lymphoma: a 50-year perspective.

Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT.

J Clin Oncol. 2014 Jan 20;32(3):163-8. doi: 10.1200/JCO.2013.53.1194. No abstract available.

PMID:
24441526
7.

Research: the moving parts.

DeVita VT Jr.

CA Cancer J Clin. 2013 Jan;63(1):5-8. doi: 10.3322/caac.21168. Epub 2012 Dec 18. No abstract available.

8.

Two hundred years of cancer research.

DeVita VT Jr, Rosenberg SA.

N Engl J Med. 2012 Jun 7;366(23):2207-14. doi: 10.1056/NEJMra1204479. Epub 2012 May 30. No abstract available.

9.

Opinion: a personal note--40 years after the signing of the Cancer Act.

DeVita VT Jr.

Nat Rev Clin Oncol. 2011 Nov 1;8(12):693-4. doi: 10.1038/nrclinonc.2011.168. No abstract available.

PMID:
22048622
10.

Hematology in 2010: New therapies and standard of care in oncology.

DeVita VT Jr, Canellos GP.

Nat Rev Clin Oncol. 2011 Feb;8(2):67-8. doi: 10.1038/nrclinonc.2010.221. Review. Erratum in: Nat Rev Clin Oncol. 2011 Jul;8(7):384.

PMID:
21278770
11.

Focus issue on biomarkers.

Hutchinson L, Devita VT.

Nat Rev Clin Oncol. 2010 Jun;7(6):295. doi: 10.1038/nrclinonc.2010.70. No abstract available.

PMID:
20517335
12.

A breakthrough in Hodgkin's disease.

DeVita VT Jr.

Nat Rev Clin Oncol. 2010 Apr;7(4):179. doi: 10.1038/nrclinonc.2010.36. No abstract available.

PMID:
20354537
13.

Toward a personalized treatment of Hodgkin's disease.

DeVita VT Jr, Costa J.

N Engl J Med. 2010 Mar 11;362(10):942-3. doi: 10.1056/NEJMe0912481. No abstract available.

PMID:
20220189
14.

Breast cancer screening and mortality.

Devita VT Jr.

Nat Rev Clin Oncol. 2010 Feb;7(2):65. doi: 10.1038/nrclinonc.2009.232. No abstract available.

PMID:
20118972
15.

Conflict of interest disclosures.

Hutchinson L, DeVita VT Jr.

Nat Rev Clin Oncol. 2010 Jan;7(1):1. doi: 10.1038/nrclinonc.2009.215. No abstract available.

PMID:
20029440
16.

The NIH entitlement program.

DeVita VT Jr.

Nat Rev Clin Oncol. 2009 Nov;6(11):613. doi: 10.1038/nrclinonc.2009.164. No abstract available.

PMID:
19861989
17.

The Holy Grail of biomarkers.

Hutchinson L, DeVita VT Jr.

Nat Rev Clin Oncol. 2009 Oct;6(10):553. doi: 10.1038/nrclinonc.2009.145. No abstract available.

PMID:
19786995
18.

We have met the enemy and he is us!

DeVita VT Jr.

Nat Rev Clin Oncol. 2009 Sep;6(9):493. doi: 10.1038/nrclinonc.2009.89. No abstract available.

PMID:
19707237
19.

The most important news at ASCO 2009.

DeVita VT Jr.

Nat Rev Clin Oncol. 2009 Jul;6(7):371. doi: 10.1038/nrclinonc.2009.93. No abstract available.

PMID:
19561629
20.

The struggles of cancer centers.

DeVita VT Jr.

Nat Rev Clin Oncol. 2009 May;6(5):241. doi: 10.1038/nrclinonc.2009.51. No abstract available.

PMID:
19390544
21.

Role of chemotherapy in Hodgkin's lymphoma.

Seam P, Janik JE, Longo DL, Devita VT Jr.

Cancer J. 2009 Mar-Apr;15(2):150-4. doi: 10.1097/PPO.0b013e3181a27018. Review.

22.

Off-label use of approved drugs.

Devita VT Jr.

Nat Rev Clin Oncol. 2009 Apr;6(4):181. doi: 10.1038/nrclinonc.2009.41. No abstract available.

PMID:
19333219
23.

News the public should rely on.

DeVita VT Jr.

Nat Clin Pract Oncol. 2009 Feb;6(2):59. doi: 10.1038/ncponc1301. No abstract available.

PMID:
19180108
24.

The clinical trials system is broken.

DeVita VT Jr.

Nat Clin Pract Oncol. 2008 Dec;5(12):683. doi: 10.1038/ncponc1263. No abstract available.

PMID:
19034294
25.

A history of cancer chemotherapy.

DeVita VT Jr, Chu E.

Cancer Res. 2008 Nov 1;68(21):8643-53. doi: 10.1158/0008-5472.CAN-07-6611.

26.

The era of personalized medicine: back to basics.

Hutchinson L, DeVita VT Jr.

Nat Clin Pract Oncol. 2008 Nov;5(11):623. doi: 10.1038/ncponc1253. No abstract available.

PMID:
18957968
27.

Trials and tribulations.

DeVita VT Jr.

Nat Clin Pract Oncol. 2008 Sep;5(9):495. doi: 10.1038/ncponc1182. No abstract available.

PMID:
18754022
28.

More on strong inference.

DeVita VT Jr.

Nat Clin Pract Oncol. 2008 May;5(5):239. doi: 10.1038/ncponc1126. No abstract available.

PMID:
18437157
29.

Strong inference.

DeVita VT Jr.

Nat Clin Pract Oncol. 2008 Apr;5(4):177. doi: 10.1038/ncponc1094. No abstract available.

PMID:
18376422
30.

Health insurance reform--beware of the general solution for the specific problem.

DeVita VT Jr.

Nat Clin Pract Oncol. 2008 Feb;5(2):59. doi: 10.1038/ncponc1046. No abstract available.

PMID:
18235439
31.

The Provenge decision.

DeVita VT Jr.

Nat Clin Pract Oncol. 2007 Jul;4(7):381. No abstract available.

PMID:
17554239
32.

A step in the right direction.

DeVita VT Jr.

Nat Clin Pract Oncol. 2006 Dec;3(12):641. No abstract available.

PMID:
17139311
33.

Let's return to the "belly bath".

DeVita VT Jr.

Nat Clin Pract Oncol. 2006 Aug;3(8):405. No abstract available.

PMID:
16894365
34.

The concept of cure.

DeVita VT Jr.

Nat Clin Pract Oncol. 2006 Feb;3(2):59. No abstract available.

PMID:
16462824
35.

Herceptin: HERalding a new era in breast cancer care but at what cost?

Hutchinson L, DeVita VT Jr.

Nat Clin Pract Oncol. 2005 Dec;2(12):595. No abstract available.

PMID:
16341094
36.

Shifting paradigms in lung cancer.

DeVita VT.

Nat Clin Pract Oncol. 2005 Nov;2(11):535. No abstract available.

PMID:
16270076
37.

Should the FDA be the doctor of last resort?

DeVita VT Jr.

Nat Clin Pract Oncol. 2005 Sep;2(9):423. No abstract available.

PMID:
16264991
38.

The Framework Convention on Tobacco Control.

DeVita VT Jr.

Nat Clin Pract Oncol. 2005 Apr;2(4):171. No abstract available.

PMID:
16264911
39.

Treatment utopia.

DeVita VT Jr.

Nat Clin Pract Oncol. 2005 Feb;2(2):59. No abstract available.

PMID:
16264858
40.

The curse of the cure.

DeVita VT Jr.

Nat Clin Pract Oncol. 2005 Jan;2(1):1. No abstract available.

PMID:
16264829
41.

The 'War on Cancer' and its impact.

DeVita VT Jr.

Nat Clin Pract Oncol. 2004 Dec;1(2):55. No abstract available.

PMID:
16264801
42.

A selective history of the therapy of Hodgkin's disease.

DeVita VT Jr.

Br J Haematol. 2003 Sep;122(5):718-27. No abstract available.

PMID:
12930382
43.

Hodgkin's disease--clinical trials and travails.

DeVita VT Jr.

N Engl J Med. 2003 Jun 12;348(24):2375-6. No abstract available. Erratum in: N Engl J Med. 2003 Jul 10;349(2):202.

PMID:
12802021
44.

On the classification of research.

DeVita VT Jr.

Cancer J. 2003 Jan-Feb;9(1):2-3. No abstract available.

PMID:
12602761
45.

Evolution of the National Cancer Program: an American investment for conquering cancer.

Hubbard SM, Mayer DK, DeVita VT Jr.

Semin Oncol Nurs. 2002 Nov;18(4):252-64. Review.

PMID:
12463057
46.

A perspective on the war on cancer.

DeVita VT Jr.

Cancer J. 2002 Sep-Oct;8(5):352-6. No abstract available.

PMID:
12416889
47.

On the classification of research.

DeVita VT Jr.

Curr Oncol Rep. 2002 Nov;4(6):453-4. No abstract available.

PMID:
12354355
48.

National Oncology Forum: perspectives for the year 2000.

DeVita VT Jr, Bleickardt EW.

Cancer J. 2001 Jul-Aug;7 Suppl 1:S2-13. Review.

PMID:
11504281
49.

A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.

Burtness B, Belker M, Stoltz M, Peccerillo KM, Lamb LA, Chmael SE, McKeon A, Clark MB, Winship J, Marsh JC, Pizzorno G, DeVita VT Jr.

Cancer J. 2000 Sep-Oct;6(5):309-15.

PMID:
11079170
50.

Therapeutic implications of the new biology.

DeVita VT Jr, Abou-Alfa GK.

Cancer J. 2000 Apr;6 Suppl 2:S113-20. Review. No abstract available.

PMID:
10803824

Supplemental Content

Loading ...
Support Center